The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Black women more likely to develop lymphedema following breast cancer treatment than white women

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

A research team at Oregon Health & Science University discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
Clinical Roundup

Researchers decipher mechanism enabling breast cancer to metastasize to the brain

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, found a mechanism that allows breast cancer to send metastases to the brain. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.
Drugs & Targets

FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer

FDA granted breakthrough therapy designation to Enhertu (trastuzumab deruxtecan) for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
Podcast

Otis Brawley looks back on a year of great science and greater challenges

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA. 
Clinical Roundup

Eflornithine + lomustine extend OS for patients with recurrent IDH mutant, grade 3 astrocytoma, phase III data show

Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free survival compared to lomustine alone in patients with recurrent IDH mutant, grade 3 astrocytoma. 
In Brief

Ben Ho Park, Sara Tolaney to receive awards at 2025 San Antonio Breast Cancer Symposium

Ben Ho ParkSara TolaneyBen Ho Park and Sara M. Tolaney will receive American Association for Cancer Research awards at the the San Antonio Breast Cancer Symposium Dec. 9-13 for their contributions to breast cancer research. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account